EMLA Drug Patent Profile

Which patents cover Emla, and what generic alternatives are available?

Emla is a drug marketed by Teva Branded Pharm and Astrazeneca and is included in two NDAs.

The generic ingredient in EMLA is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emla

A generic version of EMLA was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18^th, 2003.

Summary for EMLA

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for EMLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	EMLA	lidocaine; prilocaine	CREAM;TOPICAL	019941-001	Dec 30, 1992		DISCN	Yes	No
Astrazeneca	EMLA	lidocaine; prilocaine	DISC;TOPICAL	020962-001	Feb 4, 1998		DISCN	No	No

International Patents for EMLA

See the table below for patents covering EMLA around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	88309
Austria	A859578
Sweden	7713618
Finland	783668
Japan	S55105613	SWEAT CONTROLLING AGENT
Norway	149913
Ireland	782350

EMLA Market Analysis and Financial Projection

Last updated: February 4, 2026

What is EMLA and Why Is It Relevant to Investment Analysis?

EMLA is a topical anesthetic cream used primarily for numbing skin before procedures such as injections, needle insertions, or minor skin surgeries. Its formulation combines lidocaine and prilocaine, two local anesthetics, providing rapid onset and long-lasting anesthesia. Marketed by AstraZeneca, EMLA's global sales were approximately $300 million in 2022[1].

Given its role in minimally invasive procedures and outpatient settings, EMLA remains relevant in healthcare systems emphasizing outpatient care and pain management. The product's patent expiration in multiple jurisdictions, combined with patent litigations and biosimilar entries, influences its revenue prospects.

What Are the Market Dynamics and Growth Drivers for EMLA?

The global topical anesthetic market, including EMLA, was valued at about $1.2 billion in 2022 and is projected to grow at a CAGR of 5% over the next five years[2]. Drivers include increased outpatient procedures, rise in cosmetic dermatology, and growing demand for pain management options.

EMLA competes with generics and over-the-counter (OTC) ointments. Although over-the-counter sales account for a fraction of EMLA's revenue, their growth can erode prescription sales margins. Key regions exhibit different dynamics:

• North America: Mature market, slower growth, EMLA remains a leading prescription topical anesthetic.
• Europe: Similar to North America, with increased OTC availability.
• Asia-Pacific: Fastest growth rate, driven by expanding healthcare access and cosmetic procedures.

The timing of patent expiry in 2021 in the US and EU opened the market to generics, adding competitive pressure[3].

How Do Patent and Regulatory Factors Affect EMLA’s Investment Outlook?

EMLA’s primary patent protection expired in the US and EU in 2021. This led to increased generic entry, resulting in price erosion and revenue decline for the brand. AstraZeneca defended this market through patent litigation and formulation claims, but legal challenges have limited success.

Regulatory approval for generics in key markets flooded the market, reducing EMLA's margins. In some regions, EMLA’s formulations received OTC approval, boosting accessibility but pressuring branded sales.

Potential future regulatory issues include:

• Like for like formulations; any change may require new approvals.
• Biosimilars and new formulations entering the market, potentially capturing market share.
• Local regulatory acceptances affecting geographic expansion.

What Are the Financials and Revenue Projections for EMLA?

Historical revenue trend (approximate):

Year	Revenue (USD millions)	Notes
2020	350	Pre-patent expiry
2021	300	Post-patent expiry, market facing generic entry
2022	300	Stabilization at lower level

The revenue stabilizes around $300 million with margin compression. Future projections depend on new growth initiatives or formulations.

Cost structures are dominated by R&D, regulatory compliance, and marketing. Post-patent expiry, marketing costs decline, but competition pressures necessitate innovation or line extensions to sustain growth.

What Competitive or Strategic Risks Exist?

Key risks include:

• Price erosion from generic competition.
• Limited differentiability as formulations converge.
• Regulatory delays or rejections impacting new formulations.
• Dependence on physician prescribing habits and patient acceptance.

Potential strategic responses by AstraZeneca include investing in novel delivery systems, combining EMLA with other analgesics, or expanding into new regional markets.

What Investment Opportunities and Challenges Are Present?

Opportunities:

• Expansion into emerging markets with growing healthcare infrastructure.
• Development of improved formulations with faster onset or longer duration.
• Increasing use in cosmetic and aesthetic procedures.

Challenges:

• Market saturation and commoditization post-patent expiry.
• Erosion of branded sales margins.
• Intense competition from generics and OTC products.

Key Takeaways

EMLA remains a clinically valuable, established topical anesthetic. Patent expirations in 2021 caused a significant revenue decline, with ongoing erosion from generics and OTC alternatives. The product's future hinges on innovation, regional expansion, and overcoming competitive pressures. The outlook remains cautious; revenue may stabilize but unlikely to return to pre-expiry levels without strategic repositioning.

Investors should weigh the market’s growth potential against patent and competitive risks, considering EMLA's position within AstraZeneca's broader portfolio and pipeline strategies.

FAQs

1. Will EMLA regain market share after patent expiration?
Unlikely without innovation or reformulation, as generic competition dominates pricing and access.

2. Are there legal prospects for AstraZeneca to extend EMLA’s exclusivity?
Patent litigation has limited success; substantial extensions are improbable unless new formulations or patents are secured.

3. Can EMLA penetrate emerging markets more effectively?
Yes, as healthcare access expands, especially in Asia-Pacific, regional growth is feasible.

4. What about OTC sales?
OTC availability can increase volume but puts further pressure on priced sales and margins.

5. Is there pipeline activity related to EMLA or its class?
Currently limited, but development of new local anesthetics or formulations could influence long-term prospects.

---

Sources
[1] AstraZeneca Annual Report 2022
[2] MarketsandMarkets, Topical Anesthetics Market, 2023
[3] U.S. Patent Office, Patent expiry notices, 2021